Does Cobenfy Have the Potential to Become a Top Drug for BMY?

BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.

Bristol Myers’ BMY schizophrenia drug Cobenfy delivered a sound performance in 2025.

Cobenfy (xanomeline and trospium chloride), formerly KarXT, is an oral medication. It represents the first new pharmacological approach to treat schizophrenia in decades. The FDA approved the drug in September 2024.

The drug’s uptake has been encouraging, with sales reaching $155 million in 2025, driven by expanded access and deeper adoption across community and hospital settings.

According to BMY, Cobenfy’s uptake has outpaced all comparable schizophrenia treatments and relevant analogs in its first year on the market, with continued steady growth expected through 2026.

The uptake of Cobenfy for schizophrenia boosts BMY’s portfolio and validates the acquisition of Karuna Therapeutics.

Bristol Myers recently reported phase II data showing that adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with no new safety concerns.

The study (n=105) found low discontinuation rates (~14–15%), no dropouts due to lack of efficacy, and modest improvements in symptom and functioning scores, regardless of whether patients transitioned over two or four weeks.........

© Quartz